Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
AIDS
Conditions
AIDS, HIV Infections
Trial Timeline
Nov 1, 2004 → Sep 1, 2009
NCT ID
NCT00095576About Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placebo
Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placebo is a phase 2 stage product being developed by Merck for AIDS. The current trial status is terminated. This product is registered under clinical trial identifier NCT00095576. Target conditions include AIDS, HIV Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00095576 | Phase 2 | Terminated |
Competing Products
20 competing products in AIDS